Olmesartan Medoxomil is a widely prescribed angiotensin II receptor blocker (ARB) used to treat hypertension. Its synthesis is a multi-step process involving several key chemical intermediates, each playing a crucial role in building the final complex molecular structure. Among these, Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1H-imidazole-5-carboxylate, identified by CAS number 144689-93-0, stands out as a vital precursor. Understanding its function and sourcing requirements is essential for pharmaceutical manufacturers.

This particular imidazole derivative serves as a foundational building block in the Olmesartan Medoxomil synthesis pathway. Its structure, featuring an imidazole ring with specific functional groups, is strategically designed to be transformed through subsequent chemical reactions into the desired API. The purity of this intermediate directly influences the yield and quality of the final Olmesartan product. Therefore, sourcing high-purity Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1H-imidazole-5-carboxylate, typically with a minimum purity of 98%, is a non-negotiable requirement for pharmaceutical manufacturers.

When procurement specialists look for this compound, they often use search queries like 'buy Olmesartan intermediate CAS 144689-93-0' or 'API intermediate supplier China'. This reflects a global trend towards consolidating supply chains with efficient and quality-conscious manufacturers, particularly those located in China, which offers competitive pricing and significant production capacity. As a leading supplier of this critical intermediate, we are dedicated to meeting these demands with products that adhere to stringent quality standards.

The chemical properties of Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1H-imidazole-5-carboxylate, such as its appearance as a white powder, its molecular formula (C12H20N2O3), and molecular weight (240.30), are important identifiers. However, it is the meticulous synthesis and purification processes employed by the manufacturer that ensure its suitability for pharmaceutical use. Companies rely on Certificates of Analysis (COA) to verify these specifications and confirm the absence of detrimental impurities.

The efficient sourcing of such intermediates not only impacts production costs but also the overall timeline for bringing vital medications to market. Manufacturers who can provide consistent quality, reliable delivery, and technical support are invaluable partners. The ability to purchase this intermediate in various quantities, from research-scale to commercial bulk, further supports diverse project needs within the pharmaceutical industry.

In summary, Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1H-imidazole-5-carboxylate (CAS 144689-93-0) is indispensable for the synthesis of Olmesartan Medoxomil. As a committed manufacturer and supplier in China, we ensure that this key intermediate meets the high standards required by the pharmaceutical sector. We encourage you to contact us for your sourcing needs and to receive a competitive quote, ensuring the quality and efficiency of your pharmaceutical production.